TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02969681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: 1.5g/kg/day, D1-3, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: * mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks
Study: NCT04425135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg,D1,ivgtt, Q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg,Qd,Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrixed
Description: 500 mg/m2,D1,ivgtt, Q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5\~6,D1,ivgtt, Q3w.
Study: NCT00973609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
Description: Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.
Study: NCT04248218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation Group/Case
Description: If the patient is in the active rehabilitation group, the patient will receive instructions based on the latest CDC concussion management guidelines that specify a symptom-limited progressive return to full activities. This group will be instructed to take at least 10,000 steps a day for five days on their pedometers. In addition, they will also watch a two-minute video by the PI and research team reinforcing the active rehabilitation instructions.
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNR
Description: Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Study: NCT02017704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6
Description: * Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis.
Study: NCT00813267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cell infusion
Study: NCT04329325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Please see detailed summary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Please see detailed summary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Please see detailed summary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Please see detailed summary.
Study: NCT03764462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-101 45mg
Description: Raloxifene 45mg tablet
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCR
Description: 1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
Study: NCT03764462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-101 45mg
Description: Raloxifene 45mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg
Description: Raloxifene 60mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg
Description: Raloxifene 60mg tablet
Study: NCT03896906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: simple mask
Description: Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
Study: NCT04723004

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab combined with Bevacizumab
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Bevacizumab 15mg/kg, IV infusion, every 3 weeks (q3w), Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Control group:~Sorafenib 400mg, po, Bid, continuous administration, until occurrence of termination event specified in the protocol.
Study: NCT02715804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Description: PEGPH20 will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PEGPH20

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study: NCT04115345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study: NCT01048047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine
Description: aliskiren 300 mg /amlodipine 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren/amlodipine
Description: aliskiren 300 mg /amlodipine 10 mg
Study: NCT02607462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03778580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxamine Dihydrochloride
Description: pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03369704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Study: NCT00643097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3 vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3 vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3 vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care chemotherapy
Study: NCT01283893

Intervention type: PROCEDURE
Intervention: Laparoscopic distal gastrectomy with D2 lymphadenectomy
Description: The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.

Intervention type: PROCEDURE
Intervention: Laparoscopic distal gastrectomy with D2 lymphadenectomy
Description: The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
Study: NCT02325440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod: 0.5 mg p.o. (o.i.d)
Study: NCT00002540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Examination
Description: Undergo DRE
Study: NCT02325440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab: 300 mg i.v. (once at baseline);
Study: NCT02758912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
Study: NCT02949557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decortication + bone grafts

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decortication + bone grafts
Study: NCT05380908

Intervention type: OTHER
Intervention: None of any intervention
Description: The patients did not have any intervention.

Intervention type: OTHER
Intervention: None of any intervention
Description: The patients did not have any intervention.
Study: NCT01816542

Intervention type: OTHER
Group type: OTHER
Intervention: patch tests on healthy skin
Description: Patches will be placed on healthy skin.
Study: NCT00002540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study: NCT02932319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The Foley cathter will be inserted at term + 4 days for 24 hours.
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asp
Description: 2,000 IU/m2 IV for ages \</= 50, age \> 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: 750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
Study: NCT02932319

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: expectative
Description: expectative until the next day befor starting the induction
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal AraC
Description: 25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCV
Description: 50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
Study: NCT00646581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin)
Description: 40 IU Intranasal Insulin will be administered once
Study: NCT03499613

Intervention type: OTHER
Intervention: Multidisciplinary rehabilitation program
Description: The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
Study: NCT02517268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AraC
Description: 2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 140 mg orally daily if BCR/ABL positive and/or Ph+
Study: NCT04121689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein Concentrate
Description: The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
Study: NCT00255034

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
Study: NCT01398228

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality improvement initiatives
Description: A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality improvement initiatives
Description: A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality improvement initiatives
Description: A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality improvement initiatives
Description: A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
Study: NCT01448707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
Study: NCT03613818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO
Description: eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
Study: NCT02066545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CLS001 Topical Gel Vehicle
Study: NCT03374761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families First Home Visiting Program
Description: 10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
Study: NCT01703104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paludrine + Folic Acid
Description: This is the combination of routine drugs for treating sickle cell disease

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Paludrine + Folic Acid + Jobelyn
Description: Combination of routine drugs + Jobelyn
Study: NCT02071641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT02871518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin combine with IMRT
Description: Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin combine with IMRT
Description: Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT